Sidley represented Changchun GeneScience (GenSci) Pharmaceuticals, a China-based biotechnology company, in its exclusive out-license transaction with Yarrow Bioscience, a U.S.-based biotechnology company backed by RTW Investors, for the ex-China rights to a potential first-in-class antibody therapy for the treatment of Graves’ disease and thyroid eye disease. The transaction includes an upfront payment of US$70 million, US$50 million in near-term development milestone payments, and potential future milestone payments that could bring the total deal value to approximately US$1.37 billion. GenSci is also eligible to receive tiered double-digit royalties on future ex-China sales of the product.
The transaction was led by partner James Lu (Emerging Companies and Venture Capital) and counsel Adam Welland (Technology and Life Sciences Transactions); it included Torrey Cope (Food, Drug and Medical Device); Rollin Ransom and Eric Schwartz (Commercial Litigation and Disputes); and Jean Qiu (Technology and Life Sciences Transactions).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.